the overall complete remission rate was 27/78 ( 35 % ) in acute myelogenous leukemia and 5/9 ( 56 % ) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines ( rubidazone or adriamycin [ doxorubicin ] ) or m-amsa ( amsacrine ) .
C0023467
acute myelogenous leukemia
C0013089
doxorubicin